Aileron Therapeutics, Inc. (ALRN)
Largest Insider Buys in Sector
ALRN Stock Price History Chart
ALRN Stock Performance
About Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Insider Activity of Aileron Therapeutics, Inc.
Over the last 12 months, insiders at Aileron Therapeutics, Inc. have bought $898 and sold $281,909 worth of Aileron Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aileron Therapeutics, Inc. have bought $3.56M and sold $281,909 worth of stock each year.
Highest buying activity among insiders over the last 12 months: WINDSOR JAMES BRIAN (President and CEO) — $898.
The last purchase of 400 shares for transaction amount of $898 was made by WINDSOR JAMES BRIAN (President and CEO) on 2024‑12‑05.
List of Insider Buy and Sell Transactions, Aileron Therapeutics, Inc.
| 2024-12-05 | President and CEO | 400 0.0018% | $2.24 | $898 | -8.19% | |||
| 2024-06-17 | Sale | 10 percent owner | 4,707 0.0219% | $3.25 | $15,298 | -14.49% | ||
| 2024-06-14 | Sale | 10 percent owner | 1,900 0.009% | $3.30 | $6,270 | -14.60% | ||
| 2024-06-12 | Sale | 10 percent owner | 9,342 0.0435% | $3.25 | $30,362 | -15.08% | ||
| 2024-06-11 | Sale | 10 percent owner | 5,752 0.0269% | $3.26 | $18,744 | -14.40% | ||
| 2024-06-10 | Sale | 10 percent owner | 9,577 0.046% | $3.30 | $31,604 | -12.89% | ||
| 2024-06-07 | Sale | 10 percent owner | 1,740 0.0081% | $3.26 | $5,664 | -14.20% | ||
| 2024-06-06 | Sale | 10 percent owner | 4,284 0.0199% | $3.29 | $14,104 | -15.20% | ||
| 2024-06-05 | Sale | 10 percent owner | 6,291 0.0291% | $3.30 | $20,760 | -15.45% | ||
| 2024-05-01 | Sale | 10 percent owner | 20,315 0.1211% | $4.21 | $85,473 | -28.00% | ||
| 2024-04-30 | Sale | 10 percent owner | 90 0.0006% | $4.97 | $448 | -34.07% | ||
| 2024-04-29 | Sale | 10 percent owner | 10,746 0.0637% | $4.95 | $53,182 | -38.62% | ||
| 2023-12-15 | President and COO | 225 0.0043% | $3.37 | $758 | +2.80% | |||
| 2023-11-20 | President and COO | 5,076 0.1087% | $1.97 | $9,987 | +92.04% | |||
| 2021-01-08 | See Remarks | 9M 8.7946% | $1.10 | $9.9M | -14.81% | |||
| 2020-06-15 | director | 5,800 0.0189% | $1.22 | $7,076 | +2.50% | |||
| 2020-06-08 | 3.7M 11.0475% | $1.10 | $4.07M | +4.24% | ||||
| 2020-06-08 | director | 227,272 0.6786% | $1.10 | $249,999 | +4.24% | |||
| 2019-11-15 | director | 39,142 0.1624% | $0.51 | $19,962 | +60.68% | |||
| 2019-11-14 | director | 15,858 0.0646% | $0.51 | $8,088 | +57.84% |
Insider Historical Profitability
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 10 percent owner | 1746549 8.0613% | $2.15 | 0 | 11 | |
| WINDSOR JAMES BRIAN | President and CEO | 239 0.0011% | $2.15 | 3 | 0 | |
| Satter Muneer A | See Remarks | 16609449 76.6617% | $2.15 | 3 | 0 | <0.0001% |
| Novartis Bioventures Ltd | 10 percent owner | 2079394 9.5975% | $2.15 | 1 | 27 | <0.0001% |
| Gallagher Brian M. Jr. | director | 1431519 6.6072% | $2.15 | 1 | 0 | <0.0001% |
| APPLE TREE PARTNERS II LP | 10 percent owner | 1380241 6.3706% | $2.15 | 0 | 15 | |
| Shanafelt Armen | director | 1094987 5.054% | $2.15 | 1 | 0 | <0.0001% |
| LV Management Group, LLC | 1094987 5.054% | $2.15 | 1 | 0 | <0.0001% | |
| EXCEL MEDICAL FUND LP | 10 percent owner | 1016100 4.6899% | $2.15 | 1 | 0 | <0.0001% |
| CVF, LLC | 10 percent owner | 716180 3.3056% | $2.15 | 1 | 0 | <0.0001% |
| ROCHE HOLDING LTD | 10 percent owner | 702363 3.2418% | $2.15 | 1 | 0 | <0.0001% |
| KCK LTD. | 10 percent owner | 646817 2.9854% | $2.15 | 1 | 0 | <0.0001% |
| AJU IB Investment Co., Ltd. | 10 percent owner | 517558 2.3888% | $2.15 | 1 | 0 | <0.0001% |
| VON RICKENBACH JOSEF H | director | 445460 2.056% | $2.15 | 7 | 0 | <0.0001% |
| Sigma Emerging Markets Ltd. | 10 percent owner | 423086 1.9528% | $2.15 | 1 | 0 | <0.0001% |
| Vukovic Vojo | SVP, Chief Medical Officer | 75000 0.3462% | $2.15 | 1 | 0 | +13.56% |
| Bailey Jeffrey Allen | director | 74894 0.3457% | $2.15 | 3 | 0 | +56.3% |
| Kapnick Scott | 66666 0.3077% | $2.15 | 1 | 0 | <0.0001% | |
| Gregory Kathryn | SVP, Chief Business Officer | 45000 0.2077% | $2.15 | 1 | 0 | +7.54% |
| LONGENECKER JOHN P PHD | President and CEO | 10000 0.0462% | $2.15 | 1 | 0 | <0.0001% |
| Ambros Reinhard J. | director | 5800 0.0268% | $2.15 | 2 | 0 | <0.0001% |
| Dougherty Donald | SVP & Chief Financial Officer | 5000 0.0231% | $2.15 | 2 | 0 | <0.0001% |
| Aivado Manuel | See Remarks | 1000 0.0046% | $2.15 | 1 | 0 | <0.0001% |